"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!
News
Advertisement
Advertisement
Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.
Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.
The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.
The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.
Advertisement
According to the company, it is working with the FDA to address the agency’s issues.
Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.
OCT methods are invaluable in the assessment of patients with the condition
Advertisement
Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.
Surgeon discusses latest trends for treating cornea
This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.
A multicentre study demonstrates comparable results to FS-LASIK
VG901 is a gene therapy for CNGA1-associated RP.
Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.
The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).
According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
The geographic atrophy treatment was approved by the FDA in the US earlier this month.
The 2023 SOE meeting featured symposia, awards and a spotlight on young ophthalmologists
To heighten precision, use total keratometry, not imaginary numbers
The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.
Vitrectomy is a tool that can help surgeons curb complications
Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.
At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.
Faricimab could lower treatment burden for patients compared to aflibercept
Novel concept: inner choroid/outer retina neurovascular unit
Advertisement
Advertisement